Top Markets
#1 Nesa Nesa +859.58%
#2 MetaDAO MetaDAO +28.44%
#3 Pons Pons +16.09%
#4 Gigachad Gigachad +15.19%
#5 Utya Utya +12.45%
#6 The Black Bull The Black Bull +12.43%
#7 cat in a dogs world cat in a dogs world +11.26%
#8 Tornado Cash Tornado Cash +9.64%
#9 Solstice Solstice +9.57%
#10 COINDEPO COINDEPO +9.37%
Coin of the day
Nesa Nesa
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Celltrion, Inc. Celltrion, Inc.

Celltrion, Inc.

068270
Rang in aandelen #825
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Aandeelprijs
$132.84
Marktkapitalisatie
$30.46B
Verandering (1 dag)
-0.98%
Verandering (1 jaar)
11.23%
Land
KR
Handel Celltrion, Inc. (068270)

Categorie

Healthcare
EPS voor Celltrion, Inc. (068270)
EPS per 2026 TTM: 0
Volgens de laatste financiële rapporten en de aandelenkoers van Celltrion, Inc. is de huidige EPS van het bedrijf (TTM) 0. Eind 2026 had het bedrijf een EPS van 0, gelijk aan de EPS van 2026 die 0 bedroeg.
EPS-geschiedenis van Celltrion, Inc. van 2026 tot 2026
EPS aan het einde van elk jaar
Jaar EPS Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
EPS van vergelijkbare bedrijven of concurrenten
Bedrijf EPS EPS-verschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH